AstraZeneca PLC's PD-L1 inhibitor Imfinzi has secured approval in the US for endometrial cancer, providing competition for GSK plc's checkpoint inhibitor Jemperli and Merck & Co., Inc.'s behemoth Keytruda.
The US Food and Drug Administration has given the green light to the AstraZeneca therapy in combination with the chemotherapies...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?